The Chronic Traumatic Encephalopathy (CTE) drugs in development market research report provides comprehensive information on the therapeutics under development for Chronic Traumatic Encephalopathy (CTE), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chronic Traumatic Encephalopathy (CTE). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chronic Traumatic Encephalopathy (CTE) and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Chronic Traumatic Encephalopathy (CTE) by 14 companies/universities/institutes. The top development phase for Chronic Traumatic Encephalopathy (CTE) is preclinical with nine drugs in that stage. The Chronic Traumatic Encephalopathy (CTE) pipeline has 13 drugs in development by companies and one by universities/ institutes. Some of the companies in the Chronic Traumatic Encephalopathy (CTE) pipeline products market are: Therapeutic Solutions International, FibroGenesis and Noveome Biotherapeutics.
The key targets in the Chronic Traumatic Encephalopathy (CTE) pipeline products market include Microtubule Associated Protein Tau (Neurofibrillary Tangle Protein or Paired Helical Filament Tau or MAPT), Prolow Density Lipoprotein Receptor Related Protein 1 (Alpha 2 Macroglobulin Receptor or Apolipoprotein E Receptor or CD91 or LRP1), and Histamine Receptor (HRH).
The key mechanisms of action in the Chronic Traumatic Encephalopathy (CTE) pipeline product include Microtubule Associated Protein Tau (Neurofibrillary Tangle Protein or Paired Helical Filament Tau or MAPT) Inhibitor with three drugs in Phase I. The Chronic Traumatic Encephalopathy (CTE) pipeline products include nine routes of administration with the top ROA being Oral and seven key molecule types in the Chronic Traumatic Encephalopathy (CTE) pipeline products market including Small Molecule, and Cell Therapy.
Chronic Traumatic Encephalopathy (CTE) overview
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease linked to repeated trauma to the head. It causes the death of nerve cells in the brain, known as degeneration. First-stage symptoms are confusion, disorientation, dizziness, and headaches. Second-stage symptoms include memory loss, social instability, impulsive behavior, and poor judgment. Third and fourth stages include progressive dementia, movement disorders, hypomimia, speech impediments, sensory processing disorder, tremors, vertigo, deafness, depression and suicidality.
For a complete picture of Chronic Traumatic Encephalopathy (CTE)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
